About this trial
This study (IEDAL study) intends to prospectively enroll more than 6450 patients who will undergo head CT angiography (CTA) scanning in the outpatient clinic. It will be carried out in 21 hospitals in more than 10 provinces in China. The patient's head CTA images will be randomly assigned to the True-AI and Sham-AI group with a ratio of 1:1, and the patients and radiologists are unaware of the allocation. The primary outcomes are sensitivity and specificity of detecting intracranial aneurysms. The secondary outcomes focus on the prognosis and outcomes of the patients.
Eligibility criteria
Qualifiers
Adult inpatients and outpatients who are scheduled for head CTA scanning.
Disqualifiers
Age under 18 years.
Patients with contraindications to CTA.
Modified Rankin Scale (mRS) score > 3.
Refuse to sign informed consent.
Trial design
Treatments tested in this trial
- True-AI-integrated intracranial aneurysms diagnosis strategy
- Sham-AI-integrated intracranial aneurysms diagnosis strategy